[go: up one dir, main page]

WO2018198101A3 - Processes for the preparation of crystalline form of eluxadoline - Google Patents

Processes for the preparation of crystalline form of eluxadoline Download PDF

Info

Publication number
WO2018198101A3
WO2018198101A3 PCT/IB2018/053134 IB2018053134W WO2018198101A3 WO 2018198101 A3 WO2018198101 A3 WO 2018198101A3 IB 2018053134 W IB2018053134 W IB 2018053134W WO 2018198101 A3 WO2018198101 A3 WO 2018198101A3
Authority
WO
WIPO (PCT)
Prior art keywords
eluxadoline
processes
preparation
crystalline form
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/053134
Other languages
French (fr)
Other versions
WO2018198101A2 (en
Inventor
Sriram Hari MOHAN
Mukesh Kumar Madhra
Ketan Vithalbhai HIRPARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2018198101A2 publication Critical patent/WO2018198101A2/en
Publication of WO2018198101A3 publication Critical patent/WO2018198101A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to processes for the preparation of a crystalline form of eluxadoline.
PCT/IB2018/053134 2017-04-25 2018-05-04 Processes for the preparation of crystalline form of eluxadoline Ceased WO2018198101A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711014592 2017-04-25
IN201711014592 2017-04-25

Publications (2)

Publication Number Publication Date
WO2018198101A2 WO2018198101A2 (en) 2018-11-01
WO2018198101A3 true WO2018198101A3 (en) 2019-05-16

Family

ID=63920194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/053134 Ceased WO2018198101A2 (en) 2017-04-25 2018-05-04 Processes for the preparation of crystalline form of eluxadoline

Country Status (1)

Country Link
WO (1) WO2018198101A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015606A1 (en) 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009480A2 (en) * 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
WO2017153471A1 (en) * 2016-03-11 2017-09-14 Euticals S.P.A. New stable solvate crystalline forms of eluxadolina
WO2017221213A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
US20180029994A1 (en) * 2015-02-23 2018-02-01 Allergan Holdings Unlimited Company Process for the preparation of intermediates useful in the synthesis of eluxadoline
WO2018046028A1 (en) * 2016-09-07 2018-03-15 Zentiva, K.S. Solid forms of eluxadoline

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009480A2 (en) * 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
US20140011851A1 (en) * 2007-07-09 2014-01-09 Furiex Pharmaceuticals, Inc. Novel crystals and process of making 5-(-METHYL)-2-METHOXY-BENZOIC ACID
US20180029994A1 (en) * 2015-02-23 2018-02-01 Allergan Holdings Unlimited Company Process for the preparation of intermediates useful in the synthesis of eluxadoline
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
WO2017153471A1 (en) * 2016-03-11 2017-09-14 Euticals S.P.A. New stable solvate crystalline forms of eluxadolina
WO2017221213A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018046028A1 (en) * 2016-09-07 2018-03-15 Zentiva, K.S. Solid forms of eluxadoline

Also Published As

Publication number Publication date
WO2018198101A2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015195656A3 (en) Synthesis of polycyclic-carbamoylpyridone compounds
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2016071435A3 (en) Synthesis of copanlisib and its dihydrochloride salt
WO2018029711A3 (en) Process for the preparation of venetoclax
WO2015191945A3 (en) Solid state forms of sofosbuvir
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
WO2016009401A3 (en) Preparation of tedizolid phosphate
EP3694499A4 (en) Novel process for the preparation of lifitegrast
WO2018069941A3 (en) Polymorphic forms of venetoclax
HK1246299A1 (en) Process of making cenicriviroc and related analogs
WO2017168447A9 (en) A cyclic compounds and process for the preparation thereof
WO2016108206A3 (en) Processes for preparation of idelalisib and intermediates thereof
WO2016071362A3 (en) Herbicidal compounds
WO2015158769A8 (en) Multichamber bag opening aid
WO2016088081A8 (en) Processes for the preparation of ertugliflozin
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
WO2016181204A8 (en) Method of making a mercury based compound, mercury based compound, methods of using the mercury based compound and uses of the mercury based compound
WO2017098533A3 (en) Process for preparation of lisdexamphetamine
WO2018198101A3 (en) Processes for the preparation of crystalline form of eluxadoline
EP4403223A3 (en) Crystal forms
WO2016125185A3 (en) Process for the preparation of 4-substituted-1-(trifluoromethoxy)benzene compounds
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2016047924A3 (en) Fluorescent-labeled novel dieckol derivative
WO2017098520A8 (en) Process for the preparation of labetalol hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18791521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18791521

Country of ref document: EP

Kind code of ref document: A2